О компании rewalk robotics

О компании rewalk robotics

function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod (Nasdaq: RWLK) (“ReWalk”), the leading global exoskeleton developer and manufacturer, today announced that CEO Larry Jasinski will join Danny Danon, Israeli Ambassador to the... A Time Warner Company. prospectus): They are a medical device company that designs, develops and commercializes exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions to stand and walk once again. The ReWalk technology is designed for all-day use at home, at work, and in the community.

prospectus): They are a medical device company that designs, develops and commercializes exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions to stand and walk once again. The ReWalk technology is designed for all-day use at home, at work, and in the community. Use of the ReWalk will permit the beneficiary to stand up and ambulate both at work and in the home. ReWalk is the first exoskeleton system cleared by the FDA for both personal use as well as use in rehabilitation setting in the United States.

A.Ş. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products;  ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 20-F for the year ended December 31, 2014  filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. This description is adapted from ReWalk Robotics Ltd. “The ruling by the independent medical organization marks an important moment for exoskeletons being accepted as protocol technology for those with spinal cord injury,” said Larry Jasinski, ReWalk CEO. “Health benefit providers have historically been hesitant to acknowledge the clinical benefits in their case assessments. All Rights Reserved. _onItemRemoved=function(t){this._removed.push(t),this.delayProcessChanges()},t.prototype.delayProcessChanges=function(){var t=this;this.delayProcessChangesID||(this.delayProcessChangesID=setTimeout(function(){t.processChanges()},0))},t.prototype.processChanges=function(){var t=this;delete this.delayProcessChangesID,this._changed.forEach(function(e){t.columnsCount>1?

Use of the ReWalk will permit the beneficiary to stand up and ambulate both at work and in the home. ReWalk is the first exoskeleton system cleared by the FDA for both personal use as well as use in rehabilitation setting in the United States. A.Ş. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products;  ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 20-F for the year ended December 31, 2014  filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. This description is adapted from ReWalk Robotics Ltd. “The ruling by the independent medical organization marks an important moment for exoskeletons being accepted as protocol technology for those with spinal cord injury,” said Larry Jasinski, ReWalk CEO. “Health benefit providers have historically been hesitant to acknowledge the clinical benefits in their case assessments. All Rights Reserved.

ReWalk is the first exoskeleton system cleared by the FDA for both personal use as well as use in rehabilitation setting in the United States. A.Ş. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products;  ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 20-F for the year ended December 31, 2014  filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. This description is adapted from ReWalk Robotics Ltd. “The ruling by the independent medical organization marks an important moment for exoskeletons being accepted as protocol technology for those with spinal cord injury,” said Larry Jasinski, ReWalk CEO. “Health benefit providers have historically been hesitant to acknowledge the clinical benefits in their case assessments. All Rights Reserved. _onItemRemoved=function(t){this._removed.push(t),this.delayProcessChanges()},t.prototype.delayProcessChanges=function(){var t=this;this.delayProcessChangesID||(this.delayProcessChangesID=setTimeout(function(){t.processChanges()},0))},t.prototype.processChanges=function(){var t=this;delete this.delayProcessChangesID,this._changed.forEach(function(e){t.columnsCount>1? Any forward-looking statement made in this press release speaks only as of the date hereof. İşbu sözleşmenin aslı İngilizce’dir ve İngilizce ve Türkçe versiyonu arasında tutarsızlık olduğunda İngilizce versiyonu dikkate alınacaktır. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. (Nasdaq: RWLK) (“ReWalk”), the leading global exoskeleton developer and manufacturer, today announced the donation of... The system provides user-initiated mobility through the integration of a wearable brace support, a computer-based control system and motion sensors. All rights reserved. Lütfen finansal piyasalardaki ticari riskler ve maliyetler konusunda tam bilgi edininiz çünkü burası en riskli yatırım biçimlerinden birisidir.

(Nasdaq: RWLK) (“ReWalk”), the leading global exoskeleton developer and manufacturer, today announced that CEO Larry Jasinski will join Danny Danon, Israeli Ambassador to the... A Time Warner Company. prospectus): They are a medical device company that designs, develops and commercializes exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions to stand and walk once again. The ReWalk technology is designed for all-day use at home, at work, and in the community. Use of the ReWalk will permit the beneficiary to stand up and ambulate both at work and in the home. ReWalk is the first exoskeleton system cleared by the FDA for both personal use as well as use in rehabilitation setting in the United States. A.Ş. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products;  ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 20-F for the year ended December 31, 2014  filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. This description is adapted from ReWalk Robotics Ltd. “The ruling by the independent medical organization marks an important moment for exoskeletons being accepted as protocol technology for those with spinal cord injury,” said Larry Jasinski, ReWalk CEO. “Health benefit providers have historically been hesitant to acknowledge the clinical benefits in their case assessments. All Rights Reserved. _onItemRemoved=function(t){this._removed.push(t),this.delayProcessChanges()},t.prototype.delayProcessChanges=function(){var t=this;this.delayProcessChangesID||(this.delayProcessChangesID=setTimeout(function(){t.processChanges()},0))},t.prototype.processChanges=function(){var t=this;delete this.delayProcessChangesID,this._changed.forEach(function(e){t.columnsCount>1? Any forward-looking statement made in this press release speaks only as of the date hereof. İşbu sözleşmenin aslı İngilizce’dir ve İngilizce ve Türkçe versiyonu arasında tutarsızlık olduğunda İngilizce versiyonu dikkate alınacaktır. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

The ReWalk technology is designed for all-day use at home, at work, and in the community. Use of the ReWalk will permit the beneficiary to stand up and ambulate both at work and in the home. ReWalk is the first exoskeleton system cleared by the FDA for both personal use as well as use in rehabilitation setting in the United States. A.Ş. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products;  ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 20-F for the year ended December 31, 2014  filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. This description is adapted from ReWalk Robotics Ltd.

A Time Warner Company. prospectus): They are a medical device company that designs, develops and commercializes exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions to stand and walk once again. The ReWalk technology is designed for all-day use at home, at work, and in the community.

  • Цервициты и заболевания вульвы
  • Медгард лечебно диагностический комплекс
  • Luven medical онкологический центр
  • Справка для внж рвп
  • Диагностика на аппарате vedapulse
  • Цмрт центр клинической неврологии
  • Клиника медицинских инноваций мединнова
  • Янв новости автор sookhrob
  • Медицинский центр медстайл эффект
  • Лайков в соц сетях